We observed no evidence of hyperprogression or neoplastic T cell activation in any of our patients administered with Pembrolizumab (anti-PD-1, n = 39), and hyperprogression was also not observed in CTCL patients receiving Tislelizumab (anti-PD-1, n = 11),49 Atezolizumab (anti-PD-L1, n = 17),50 or Durvalumab (anti-PD-L1, n = 23).51 This evidence concerns the gene CD274 and primary cutaneous T-cell non-Hodgkin lymphoma.